WHY DO DEMOCRATS WANT PEOPLE TO DIE?

by Glenn Reynolds

Expensive Prescription Drugs Are a Bargain: The Inflation Reduction Act gives the government the ability to ‘negotiate’ prices. People will die.

Virtually no products are more valuable than the modern medicines produced by the biopharmaceutical industry. They cure diseases and extend lives. We’ve all heard that Americans pay higher drug prices than people in other countries. That’s true, but only when comparing retail prices of brand-name drugs. Very few Americans pay retail prices; most pay a fraction—a copay dictated by their insurance plan. Most country-to-country comparisons also leave out generics. Nine of 10 prescriptions in the U.S. are filled with generic drugs priced lower than in most other countries.

In many countries, the government is the sole purchaser of pharmaceuticals. For a new drug to be used, the government must buy and distribute it. If the government declines, the drug won’t be available. These governments negotiate with a take-it-or-leave-it attitude. Drug companies often take it, because once research and development costs are covered, some money is better than no money.

Except in rare cases, pharmaceutical companies develop drugs for the U.S. market. For drugs that make it in America, potential sales in Europe, Japan, Canada, China and elsewhere are gravy. Drugs that can’t make it in the U.S. are scuttled. Probable success in America is a necessary and sufficient condition for the development of new drugs. There are four main reasons for this:

First, the U.S. is a relatively large country. Second, the U.S. is a wealthy country; Americans are 46% richer than the British, 59% richer than the French, and 36% richer than the Germans as measured by per capita gross domestic product. Third, negotiating prices with government bureaucrats takes time, resulting in one to two years of lost sales. Fourth, prices in the U.S. are somewhat more influenced by market forces and, until the Inflation Reduction Act, weren’t determined by negotiations with the government.

Where CMS is concerned, “negotiations” is a “Godfather”-esque euphemism. If a drug company doesn’t accept the CMS price, it will be taxed up to 95% on its Medicare sales revenue for that drug. This penalty is so severe, Eli Lilly CEO David Ricks reports that his company treats the prospect of negotiations as a potential loss of patent protection for some products.

Drug research and development involves enormous fixed costs. As of 2013, the cost per new drug approved by the Food and Drug Administration was $2.9 billion. Historically, these fixed costs have doubled in real terms every nine years. So in 2022, the inflation-adjusted fixed cost per approved drug is close to $7 billion.

That huge cost must be spread out over a small fraction of the world’s population during a limited period of marketing exclusivity. Without wealthy American consumers and insurers who pay retail or close to it for brand-name drugs, some drugs won’t be developed at all. While it’s true that foreign governments mostly free-ride on the enormous investments in R&D made by the U.S., it’s also true that somebody has to pay. If nobody pays, many treatments that would improve and extend people’s lives won’t exist.

Research by Columbia University economist Frank Lichtenberg suggests that 73% of the increase in life expectancy that high-income countries experienced between 2006 and 2016 was due solely to the adoption of modern drugs. He also found that the pharmaceutical expenditure per life-year saved was $13,904 across 26 high-income countries and $35,817 in the U.S. Most Americans would pay $36,000 to live an extra year.

Ideally, of course, the U.S. would encourage other nations to pay their fair share. But that “fair share” talk only ever seems aimed at Americans who already pay a lot of taxes. I also note that when the less developed countries lecture the U.S. on “climate change damages,” they never talk about offsetting things like this.

We are primarily funded by readers. Please subscribe and donate to support us!

Biden celebrates ‘Inflation Reduction Act’ as food, rent prices climb.

Biden to Pay $80 Per Barrel to Fill Strategic Oil Reserve – Two Years After Democrats Blocked Trump From Filling Reserve at $24 Per Barrel

Joe Biden and the Democrats destroy everything they touch.

The Biden Regime is looking to pay $80 per barrel to fill the Strategic Petroleum Reserve.

Biden waged a war on domestic oil production as soon as he was sworn into office.

On his first day in office, Joe Biden killed off 42,100 jobs by ending construction of the Keystone XL Pipeline and the end of construction of the Trump border wall.

The national average for a gallon of gas is $3.841 – nearly $2 a gallon increase since he took over.

The Biden regime also shut down more pipelines last winter as gas prices were surging.

After waging a war on domestic production, Joe Biden (possibly illegally) released millions of barrels of oil from US Strategic Oil Reserves.

Biden released millions of barrels in these reserves but the beneficiaries were Asian countries and Europe.

Views:

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.